Fosaprepitant, sold under the brand names Emend (US) and Ivemend (EU) among others, is an antiemetic medication,[6] administered intravenously. It is a prodrug of aprepitant.
Clinical data | |
---|---|
Trade names | Emend, Ivemend |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a604003 |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | n/a |
Protein binding | >95% (aprepitant) |
Metabolism | To aprepitant |
Elimination half-life | 9 to 13 hours (aprepitant) |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C23H22F7N4O6P |
Molar mass | 614.414 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
Fosaprepitant was developed by Merck & Co. and was approved for medical use in the United States,[7] and in the European Union in January 2008.[5]